Lineage Cell Therapeutics, Inc.
LCTXBiotechnology
$1.03−0.96%As of Oct 29vs prior close
- Market cap
- $260.5M
- P/E (TTM)
- –
- From 52W high
- −47.45%
- EPS (LTM)
- -$0.19
- Revenue (LTM)
- $13.1M
- Net margin
- -246.58%
- Dividend yield
- 0.00%
Nomior Score
23
Steady ProfileSpeculativeBottom 9% of the scored universe
Growth48
Quality41
Value43
Momentum5
Resilience38
Growth
+10.51%revenue a year over 9 fiscal years
YE16 $5.9MLTM $13.1M
Connections
Revenue to profitQ2 YE26
The operating loss was 835% of revenue, wider by 119 pts on a year.
Who owns it
2funds